Static tool
Regulatory status checker
Static interactive checker: select a metabolic peptide molecule and see its UK / EU / US regulatory status, prescription-only / investigational / research-only flag, human-use warning and related pages. No API.
UK prescription medicine
Tirzepatide
Brand(s): Mounjaro (UK/EU/US for T2D and obesity); Zepbound (US obesity brand)
- UK status
- MHRA-licensed prescription-only medicine for type 2 diabetes and for chronic weight management in eligible adults.
- EU status
- EMA-licensed via EPAR (Mounjaro).
- US status
- FDA-approved (Mounjaro for T2D; Zepbound for weight management).
- Prescription-only
- Yes (UK POM)
- Research-only
- No
- Investigational
- No
- Licensed indications (summary)
- T2D glycaemic control; chronic weight management in adults with BMI ≥30 (or ≥27 with weight-related comorbidities); UK label extended for moderate-to-severe OSA in adults with obesity per recent regulatory action.
- Sport / WADA note
- Athletes should verify status through their relevant anti-doping authority before use.
- Last reviewed
- 20 May 2026
Human-use warning: Tirzepatide is a UK prescription-only medicine. Access must be via a qualified UK prescriber following appropriate clinical assessment. Off-label, compounded or grey-market versions are not the same regulated product.
Full molecule profile: Tirzepatide profile →
For context see the UK regulatory status hub and research-only vs prescription medicines.
What this tool does not do
- It does not advise on whether a molecule is right for any individual.
- It does not provide prescribing or dosing recommendations.
- It does not link to or recommend any supplier.
- It does not replace the MHRA register, the EMA EPAR or the FDA label.
Last reviewed 20 May 2026 · regulatory status checker · Metabolic Peptides editorial team